Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Bempedoic acid (with ezetimibe)	TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
Bendroflumethiazide tablets		2.5mg dose (higher doses not indicated in hypertension). Most patients do not develop hypokalaemia. Suggest check potassium level one month after initiation and annually thereafter (MeReC 10/94)
Benzoyl peroxide
Benzoyl peroxide 5% with clindamycin 1% (Duac®) once daily
Benzydamine 0.15% oral rinse
Benzydamine 0.15% oral spray
Betahistine tablets
Betamethasone 0.1% with neomycin 0.5% eardrops (Betnesol N)
Betamethasone ear drops
Betamethasone eye/ear/nose drops

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.